title: Effect of type II diabetes on male rat bladder contractility.
abstract: Type II diabetes is the most prevalent form of diabetes. One of the primary complications of diabetes that significantly affects quality of life is bladder dysfunction. Many studies on diabetic bladder dysfunction have been performed in models of type I diabetes; however, few have been performed in animal models of type II diabetes. Using the Zucker Diabetic Fatty (ZDF) rat model of type II diabetes, we examined the contractility and sensitivity of bladder smooth muscle in response to mediators of depolarization-induced contraction, muscarinic receptor-mediated contraction, ATP-induced contraction, and neurogenic contraction. Studies were performed at 16 and 27 wk of age to monitor the progression of diabetic bladder dysfunction. Voiding behavior was also quantified. The entire bladder walls of diabetic rats were hypertrophied compared with that of control rats. Contractility and sensitivity to carbachol and ATP were increased at 27 wk in bladder smooth muscle strips from diabetic rats, suggesting a compensated state of diabetic bladder dysfunction. Purinergic signaling was increased in response to exogenous ATP in bladders from diabetic animals; however, the purinergic component of neurogenic contractions was decreased. The purinergic component of neurogenic contraction was reduced by P2X receptor desensitization, but was unchanged by P2X receptor inhibition in diabetic rats. Residual and tetrodotoxin-resistant components of neurogenic contraction were increased in bladder strips from diabetic animals. Overall, our results suggest that in the male ZDF rat model, the bladder reaches the compensated stage of function by 27 wk and has increased responsiveness to ATP.
authors.affiliation: Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania; and.
authors.forename: Derek M
authors.initials: DM
authors.lastname: Kendig
authors.affiliation: Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania; and.
authors.forename: Hillevi K
authors.initials: HK
authors.lastname: Ets
authors.affiliation: Department of Pharmacology and Physiology, Drexel University College of Medicine, Philadelphia, Pennsylvania; and Department of Pathology and Laboratory Medicine, Drexel University College of Medicine, Philadelphia, Pennsylvnia robert.moreland@drexelmed.edu.
authors.forename: Robert S
authors.initials: RS
authors.lastname: Moreland
mesh_terms: D000255:Adenosine Triphosphate / Q000494:pharmacology; D000375:Aging / Q000473:pathology; D000818:Animals; D002217:Carbachol / Q000494:pharmacology; D003924:Diabetes Mellitus, Type 2 / Q000473:pathology*; D004558:Electric Stimulation; D006984:Hypertrophy; D066298:In Vitro Techniques; D007537:Isometric Contraction; D008297:Male; D018721:Muscarinic Agonists / Q000494:pharmacology; D051381:Rats; D011924:Rats, Zucker; D001743:Urinary Bladder / Q000473:pathology*; D001750:Urinary Bladder, Neurogenic / Q000473:pathology; D014554:Urination
chemical_list: D018721:Muscarinic Agonists; D000255:Adenosine Triphosphate; D002217:Carbachol
keywords: Zucker diabetic fatty rat; diabetic bladder dysfunction; electrical field stimulation; muscarinic receptors; purinergic receptors
references.citation: J Urol. 2009 Dec;182(6 Suppl):S38-44
references.pmid: 19846131
references.citation: J Urol. 1994 Aug;152(2 Pt 1):537-43
references.pmid: 8015108
references.citation: Diabetes Obes Metab. 2005 Jul;7(4):307-17
references.pmid: 15955116
references.citation: J Urol. 1982 Dec;128(6):1368-71
references.pmid: 6296468
references.citation: J Urol. 2008 Dec;180(6):2701-5
references.pmid: 18951563
references.citation: J Urol. 1993 Dec;150(6):2007-12
references.pmid: 8230554
references.citation: J Physiol. 2013 Jun 15;591(12):2971-86
references.pmid: 23613531
references.citation: J Urol. 2006 Jul;176(1):380-6
references.pmid: 16753447
references.citation: PLoS One. 2012;7(11):e48507
references.pmid: 23144896
references.citation: Diabetes Care. 2009 Apr;32(4):664-70
references.pmid: 19171725
references.citation: Urology. 2012 Oct;80(4):951.e9-16
references.pmid: 22901825
references.citation: Br J Pharmacol. 1995 Apr;114(8):1557-62
references.pmid: 7599923
references.citation: Br J Nutr. 2000 Mar;83 Suppl 1:S5-8
references.pmid: 10889785
references.citation: J Pharmacol Exp Ther. 2009 Mar;328(3):940-50
references.pmid: 19050171
references.citation: Metabolism. 2000 May;49(5):684-8
references.pmid: 10831184
references.citation: J Urol. 1999 Nov;162(5):1833-9
references.pmid: 10524944
references.citation: Chin Med J (Engl). 2014;127(7):1357-64
references.pmid: 24709194
references.citation: Nature. 2006 Dec 14;444(7121):875-80
references.pmid: 17167476
references.citation: J Urol. 2009 Dec;182(6 Suppl):S18-26
references.pmid: 19846137
references.citation: Am J Physiol Renal Physiol. 2004 Oct;287(4):F690-9
references.pmid: 15198926
references.citation: Int J Urol. 2014 Aug;21(8):831-5
references.pmid: 24661252
references.citation: J Urol. 2006 Oct;176(4 Pt 1):1493-9
references.pmid: 16952667
references.citation: J Recept Signal Transduct Res. 2005;25(3):147-57
references.pmid: 16194931
references.citation: J Physiol. 2012 Oct 15;590(20):5107-21
references.pmid: 22890701
references.citation: Annu Rev Pharmacol Toxicol. 1988;28:389-409
references.pmid: 2454609
references.citation: Biomed Res. 2009 Dec;30(6):331-5
references.pmid: 20051641
references.citation: Am J Physiol Renal Physiol. 2010 Jan;298(1):F72-7
references.pmid: 19889955
references.citation: Br J Pharmacol. 1993 Dec;110(4):1491-5
references.pmid: 8306091
references.citation: Nat Clin Pract Urol. 2006 Apr;3(4):206-15
references.pmid: 16607369
references.citation: Basic Clin Pharmacol Toxicol. 2010 Jul;107(1):603-13
references.pmid: 20406212
references.citation: Eur J Pharmacol. 2003 Sep 30;478(1):73-80
references.pmid: 14555187
references.citation: Am J Physiol Renal Physiol. 2005 Jun;288(6):F1220-6
references.pmid: 15687244
references.citation: BJU Int. 2011 Jan;107(2):192-204
references.pmid: 21208364
references.citation: In Vivo. 2006 Jan-Feb;20(1):1-4
references.pmid: 16433020
references.citation: Curr Bladder Dysfunct Rep. 2010 Aug 26;5(4):219-224
references.pmid: 21572572
references.citation: J Urol. 2009 Dec;182(6 Suppl):S8-13
references.pmid: 19846143
references.citation: FASEB J. 2001 Feb;15(2):312-21
references.pmid: 11156947
references.citation: BJU Int. 2001 May;87(7):617-22
references.pmid: 11350400
references.citation: J Urol. 1994 Feb;151(2):496-502
references.pmid: 8283565
references.citation: J Neurosci. 2007 Jan 24;27(4):845-51
references.pmid: 17251425
references.citation: Eur J Pharmacol. 1984 Apr 6;99(4):295-302
references.pmid: 6145602
references.citation: J Urol. 1991 Feb;145(2):417-22
references.pmid: 1846433
references.citation: Br J Pharmacol. 2012 Jun;166(3):877-94
references.pmid: 22352879
references.citation: Br J Pharmacol. 1972 Mar;44(3):451-61
references.pmid: 4339250
references.citation: Eur Urol. 1981;7(4):211-4
references.pmid: 7227400
references.citation: Br J Pharmacol. 2011 Jul;163(6):1276-88
references.pmid: 21391978
references.citation: Diabetes Care. 2001 Feb;24(2):412
references.pmid: 11213906
references.citation: Ilar News. 1990 Jan;32(3):13-15
references.pmid: 34191867
references.citation: Neurourol Urodyn. 2011 Jan;30(1):174-82
references.pmid: 20860017
references.citation: Neurosci Lett. 2007 Aug 9;423(1):1-5
references.pmid: 17630213